110
Participants
Start Date
April 17, 2013
Primary Completion Date
May 18, 2016
Study Completion Date
May 18, 2016
PCI-32765 (Ibrutinib)
560 mg capsules administered orally once daily, continuously on a 21-day cycle until progressive disease.
Los Angeles
Stanford
Washington D.C.
Atlanta
Chicago
Westwood
Lexington
Louisville
Baltimore
Detroit
Hackensack
New Brunswick
New York
Greenville
Portland
Philadelphia
Pittsburgh
Houston
Burlington
Seattle
Adelaide
Concord
Melbourne
Milton
Prahran
Courrière
Ghent
Leuven
Créteil
Nice
Nîmes
Paris
Pessac
Pierre-Bénite
Rennes
Cologne
Heidelberg
Mainz
Ulm
Krakow
Warsaw
Wroclaw
Moscow
Nizhny Novgorod
Saint Petersburg
Volgograd
Yekaterinburg
Barcelona
Marbella
Salamanca
Liverpool
London
Manchester
Southampton
Collaborators (1)
Pharmacyclics LLC.
INDUSTRY
Janssen Research & Development, LLC
INDUSTRY